On Dec. 5, according to the clinical trials website, Merck Sharp & Dohme registered a study titled “A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)”. in Participants With Previously Untreated DLBCL (MK-2140-010)” (waveLINE-010).
The study will start in December 2025 with a planned enrollment of 1,046 cases.The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Overexpression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) contributes to cancer cell proliferation, survival and migration, playing crucial roles in tumor development. ROR1 has been proposed as a potential therapeutic target for cancer treatment. Learn more about our ROR1 catalog.
